Page last updated: 2024-11-13
kgp94
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
KGP94: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 25234575 |
| SCHEMBL ID | 6337731 |
| MeSH ID | M0584793 |
Synonyms (11)
| Synonym |
|---|
| [(e)-[(3-bromophenyl)(3-hydroxyphenyl)methylidene]amino]thiourea |
| kgp94 |
| gtpl6533 |
| SCHEMBL6337731 |
| HY-118762 |
| MS-25407 |
| 1131456-28-4 |
| kgp 94 |
| kgp-94 |
| CS-0068464 |
| [(z)-[(3-bromophenyl)-(3-hydroxyphenyl)methylidene]amino]thiourea |
Research Excerpts
Overview
KGP94 is a potent, selective, and competitive inhibitor of the lysosomal endopeptidase enzyme (Cathepsin L) Currently in preclinical trials for the treatment of metastatic cancer.
| Excerpt | Reference | Relevance |
|---|---|---|
| "KGP94 is a potent, selective, and competitive inhibitor of the lysosomal endopeptidase enzyme (Cathepsin L) currently in preclinical trials for the treatment of metastatic cancer, which is a leading cause of cancer-associated death. " | ( An efficient and concise synthesis of a selective small molecule non-peptide inhibitor of cathepsin L: KGP94. Munikishore, R; Wang, LL; Zhang, S; Zhao, QS; Zuo, Z, 2021) | 2.28 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||